Cencora, Inc. COR
Set alert
330.84 USD +0.31 +0.09%
At close · Oct 30
326.52 -4.32 -1.31%
After hours · Oct 30, 6:51 PM ET
330.20 Day range 340.19
252.74 52-week range 374.75
- YTD
- -2.05%
- 1 year
- -3.04%
- Open
- 336.79
- Prev close
- 330.53
- Mkt cap
- 63.13B
- Vol
- 1.35M
- Avg vol
- 1.31M
- EPS
- 13.47
- P/E
- 24.56
- Div yield
- 0.73%
More statistics
- Low
- 330.20
- High
- 340.19
- Forward P/E
- 16.79
- Beta
- 0.58
- Short ratio
- 3.16
- Inst. own
- 99.25%
- Dividend
- 2.40
- Ex-div date
- Aug 13, 2026
- Earnings
- Nov 4, 2026
- 50-d avg
- 323.06
- 200-d avg
- 317.18
- 1y target
- 369.08
5Y chart
Events in this range
- Nov 12, 2021Dividend: 0.46
- Dec 1, 2021Dividend: 1.27
- Feb 11, 2022Dividend: 0.46
- May 13, 2022Dividend: 0.46
- Aug 12, 2022Dividend: 0.46
- Nov 10, 2022Dividend: 0.485
- Feb 9, 2023Dividend: 0.485
- May 11, 2023Dividend: 0.485
- Aug 10, 2023Dividend: 0.485
- Nov 10, 2023Dividend: 0.51
- Feb 8, 2024Dividend: 0.51
- May 9, 2024Dividend: 0.51
- Aug 9, 2024Dividend: 0.51
- Nov 15, 2024Dividend: 0.55
- Feb 14, 2025Dividend: 0.55
- May 16, 2025Dividend: 0.55
- Aug 6, 2025Earnings: 4; estimate 3.85; surprise 3.9%
- Aug 15, 2025Dividend: 0.55
- Nov 5, 2025Earnings: 3.84; estimate 3.79; surprise 1.32%
- Nov 14, 2025Dividend: 0.6
- Feb 4, 2026Earnings: 4.08; estimate 4.05; surprise 0.74%
- Feb 13, 2026Dividend: 0.6
- May 6, 2026Earnings: 4.75; estimate 4.82; surprise -1.45%
- May 15, 2026Dividend: 0.6
- Aug 5, 2026Earnings: 4.48; estimate 4.35; surprise 2.99%
- Aug 14, 2026Dividend: 0.6
- Sep 8, 2026Rating: RBC Capital · Sector Perform → Sector Perform
- Oct 7, 2026Rating: Leerink Partners · Outperform → Outperform
- Oct 16, 2026Rating: UBS · Buy → Buy
- Oct 20, 2026Rating: Argus Research · Buy → Buy
- Oct 22, 2026Rating: Baird · Outperform → Outperform
- Oct 30, 2026Rating: Morgan Stanley · Overweight → Overweight
- Nov 4, 2026Earnings: —; estimate 4.58; surprise —%
Signals (86)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 5, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 14, 2026 | 1 month ago |
| SMA: Bullish | Aug 17, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 6, 2026 | 3 months ago |
| SMA: Bullish | Jun 22, 2026 | 4 months ago |
| RSI: Oversold | May 4, 2026 | 6 months ago |
| SMA: Bearish | Mar 16, 2026 | 7 months ago |
| SMA: Bearish | Mar 9, 2026 | 7 months ago |
| RSI: Overbought | Feb 23, 2026 | 8 months ago |
| SMA: Bullish | Jan 12, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 22, 2025 | 10 months ago |
| SMA: Bearish | Dec 15, 2025 | 10 months ago |
| SMA: Bullish | Dec 8, 2025 | 10 months ago |
| SMA: Bearish | Dec 1, 2025 | 11 months ago |
| RSI: Overbought | Oct 13, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 6, 2025 | 1 year ago |
| SMA: Bullish | Sep 22, 2025 | 1 year ago |
| SMA: Bearish | Sep 15, 2025 | 1 year ago |
| SMA: Bullish | Sep 1, 2025 | 1 year ago |
| SMA: Bearish | Jul 14, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 7, 2025 | 1 year ago |
| RSI: Overbought | Jun 23, 2025 | 1 year ago |
| RSI: Overbought | May 19, 2025 | 1 year ago |
| RSI: Overbought | Mar 31, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 20, 2025 | 1 year ago |
| SMA: Bullish | Jan 13, 2025 | 1 year ago |
| SMA: Bullish | Jan 6, 2025 | 1 year ago |
| MACD: Sell Signal | Dec 16, 2024 | 1 year ago |
| SMA: Bearish | Dec 9, 2024 | 1 year ago |
| SMA: Bearish | Dec 9, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 4, 2024 | 1 year ago |
| SMA: Bullish | Oct 14, 2024 | 2 years ago |
| SMA: Bullish | Oct 14, 2024 | 2 years ago |
| SMA: Bearish | Sep 16, 2024 | 2 years ago |
| SMA: Bearish | Sep 16, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 16, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 9, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 2, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 12, 2024 | 2 years ago |
| SMA: Bullish | Jul 29, 2024 | 2 years ago |
| SMA: Bullish | Jul 22, 2024 | 2 years ago |
| SMA: Bearish | Jun 24, 2024 | 2 years ago |
| SMA: Bearish | Jun 24, 2024 | 2 years ago |
| SMA: Bullish | Jun 3, 2024 | 2 years ago |
| SMA: Bullish | May 27, 2024 | 2 years ago |
| SMA: Bearish | May 20, 2024 | 2 years ago |
| SMA: Bearish | Apr 29, 2024 | 2 years ago |
| RSI: Overbought | Apr 22, 2024 | 2 years ago |
| SMA: Bullish | Apr 15, 2024 | 2 years ago |
| SMA: Bearish | Apr 8, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 8, 2024 | 2 years ago |
| RSI: Overbought | Jan 1, 2024 | 2 years ago |
| MACD: Buy Signal | Oct 30, 2023 | 3 years ago |
| SMA: Bullish | Oct 2, 2023 | 3 years ago |
| SMA: Bearish | Sep 25, 2023 | 3 years ago |
| SMA: Bullish | Sep 18, 2023 | 3 years ago |
| MACD: Sell Signal | Aug 14, 2023 | 3 years ago |
| SMA: Bearish | Jul 31, 2023 | 3 years ago |
| RSI: Overbought | Jun 19, 2023 | 3 years ago |
| MACD: Buy Signal | Apr 17, 2023 | 3 years ago |
| SMA: Bullish | Mar 27, 2023 | 3 years ago |
| SMA: Bullish | Mar 20, 2023 | 3 years ago |
| SMA: Bearish | Mar 6, 2023 | 3 years ago |
| MACD: Sell Signal | Jan 23, 2023 | 3 years ago |
| SMA: Bearish | Jan 9, 2023 | 3 years ago |
| SMA: Bullish | Oct 24, 2022 | 4 years ago |
| MACD: Buy Signal | Oct 24, 2022 | 4 years ago |
| SMA: Bullish | Oct 17, 2022 | 4 years ago |
| SMA: Bearish | Sep 12, 2022 | 4 years ago |
| SMA: Bearish | Aug 22, 2022 | 4 years ago |
| SMA: Bullish | Aug 8, 2022 | 4 years ago |
| SMA: Bullish | Aug 8, 2022 | 4 years ago |
| SMA: Bearish | Aug 1, 2022 | 4 years ago |
| SMA: Bullish | Jul 25, 2022 | 4 years ago |
| SMA: Bearish | Jun 27, 2022 | 4 years ago |
| SMA: Bullish | Jun 20, 2022 | 4 years ago |
| SMA: Bearish | Jun 13, 2022 | 4 years ago |
| SMA: Bearish | May 30, 2022 | 4 years ago |
| SMA: Bullish | May 23, 2022 | 4 years ago |
| SMA: Bearish | May 9, 2022 | 4 years ago |
| SMA: Bullish | May 2, 2022 | 4 years ago |
| SMA: Bearish | Apr 25, 2022 | 4 years ago |
| RSI: Overbought | Mar 14, 2022 | 4 years ago |
| RSI: Overbought | Feb 28, 2022 | 4 years ago |
Key statistics
- Market cap
- 63.37B
- Enterprise value
- 74.91B
- Trailing P/E
- 24.65
- Forward P/E
- 16.79
- PEG ratio
- 0.69
- Price / sales
- 0.19
- Price / book
- 20.77
- EPS (TTM)
- 13.47
- Beta
- 0.58
- Dividend yield
- 0.73%
- Payout ratio
- 17.45%
- Profit margin
- 0.79%
- Revenue (TTM)
- 332.77B
- Revenue growth
- 5.10%
- Free cash flow
- 2.04B
- Total cash
- 2.82B
- Total debt
- 14.46B
- Return on equity
- 96.87%
- Shares outstanding
- 190.83M
- Short % of float
- 2.35%
- 50-day average
- 323.06
- 200-day average
- 317.18
Analyst view
Consensus: buy
Buy
Price target (mean) 369.08 +11.6% upside
Now 330.84
- Target (low)
- 330.00
- Target (mean)
- 369.08
- Target (high)
- 400.00
Ratings (0m) 14 10 buy · 4 hold · 0 sell
- Strong buy3
- Buy7
- Hold4
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 4.57.
Financials — quick view
COR Revenue — quarterly 84.75B
COR Net income — quarterly 763.52M
COR EPS — quarterly 3.95
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 4.58 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | 4.35 | 4.48 | +0.13 | +2.99% |
| May 6, 2026 | Mar 31, 2026 | 4.82 | 4.75 | -0.07 | -1.45% |
| Feb 4, 2026 | Dec 31, 2025 | 4.05 | 4.08 | +0.03 | +0.74% |
| Nov 5, 2025 | Sep 30, 2025 | 3.79 | 3.84 | +0.05 | +1.32% |
| Aug 6, 2025 | Jun 30, 2025 | 3.85 | 4.00 | +0.15 | +3.90% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Oct 22, 2026 | Baird | main | Outperform | Outperform |
| Oct 20, 2026 | Argus Research | main | Buy | Buy |
| Oct 16, 2026 | UBS | main | Buy | Buy |
| Oct 7, 2026 | Leerink Partners | main | Outperform | Outperform |
| Sep 8, 2026 | RBC Capital | reit | Sector Perform | Sector Perform |
About Cencora, Inc.
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical Distribution
- Country
- United States
- Website
- cencora.com
News
- Morgan Stanley Maintains Overweight on Cencora, Raises Price Target to $377
- Cencora Gears Up to Report Q4 Results: How to Play the Stock?
- Unveiling Cencora (COR) Q4 Outlook: Wall Street Estimates for Key Metrics
- Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth
- Cencora to Acquire AON in $2.4B Deal to Expand Oncology Network
- BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Surgery Partners, Inc. (Nasdaq – SGRY), Range Resources Corporation (NYSE – RRC), American Oncology Network, Inc. (OTCQX – AONC), Utz Brands, Inc. (NYSE – UTZ)
- Baird Maintains Outperform on Cencora, Raises Price Target to $375
- BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Passage Bio, Inc. (Nasdaq – PASG), American Oncology Network, Inc. (OTCQX – AONC), Utz Brands, Inc. (NYSE – UTZ), Finward Bancorp (Nasdaq – FNWD)
- Here’s How Much You Would Have Made Owning Cencora Stock In The Last 5 Years
- Cencora to acquire American Oncology Network in $2.4 billion deal
Your note
Sign in to keep a note on COR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BATTAGLIA SILVANA | Officer | Stock Award(Grant) | Jun 29, 2026 | 23,624 |
| CAMPBELL ELIZABETH S | Officer | Sale | Aug 23, 2026 | 19,455 |
| CLEARY JAMES F. JR. | Chief Financial Officer | Conversion of Exercise of derivative security | Mar 10, 2026 | 160,357 |
| COLLIS STEVEN HOWARD | Officer and Director | Sale | Sep 15, 2025 | 305,913 |
| DURCAN DERMOT MARK | Director | Purchase | Jun 17, 2026 | 31,767 |
| GREENBERG LON R | Director | Sale | Sep 15, 2026 | 17,128 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.54% | 18,213,783 | 6.05B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.49% | 12,378,943 | 4.11B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.04% | 9,611,756 | 3.19B | Jun 29, 2026 |
| State Street Corporation | 4.86% | 9,273,983 | 3.08B | Jun 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 3.88% | 7,410,910 | 2.46B | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 3.74% | 7,132,687 | 2.37B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.07% | 5,867,758 | 1.95B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.64% | 5,041,886 | 1.67B | Jun 29, 2026 |
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 2.33% | 4,437,584 | 1.47B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund | 2.10% | 4,005,017 | 1.33B | Jun 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.59% | 3,033,825 | 1.01B | Jul 30, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 2,543,056 | 844.43M | Sep 29, 2026 |